Share on StockTwits
 

GlaxoSmithKline (LON:GSK)‘s stock had its “hold” rating reaffirmed by Panmure Gordon in a research note issued on Wednesday, AR Network reports. They currently have a GBX 1,750 ($28.73) target price on the stock. Panmure Gordon’s price objective suggests a potential upside of 5.33% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Credit Suisse reiterated an “underperform” rating on shares of GlaxoSmithKline in a research note to investors on Thursday, January 16th. They now have a GBX 1,500 ($24.62) price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note to investors on Tuesday, January 14th. They now have a GBX 1,750 ($28.73) price target on the stock. Finally, analysts at UBS AG initiated coverage on shares of GlaxoSmithKline in a research note to investors on Friday, January 10th. They set a “neutral” rating on the stock. Five equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company. GlaxoSmithKline presently has an average rating of “Hold” and an average target price of GBX 1,618.66 ($26.57).

GlaxoSmithKline (LON:GSK) traded down 0.36% during mid-day trading on Wednesday, hitting GBX 1655.50. The stock had a trading volume of 2,983,646 shares. GlaxoSmithKline has a 1-year low of GBX 1398.00 and a 1-year high of GBX 1816.00. The stock’s 50-day moving average is GBX 1599. and its 200-day moving average is GBX 1629.. The company’s market cap is £79.745 billion.

GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.